Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma

BMC Cancer

Table 2 Antitumor effectiveness of triple mIL-12 gene electrotransfer alone or combined with irradiation on SA-1 sarcoma

Therapeutic group	N	DT (days; AM ± SE)*	GD (days; AM ± SE)**	Cures^†(%; n)	SC resistance (n)^#
Control	10	3.4 ± 0.4	-	0
3× EP	10	6.0 ± 1.0	2.7 ± 1.0	0
3× dsRed	10	3.1 ± 0.3	−0.3 ± 0.3	0
3× EGT dsRed	12	6.8 ± 0.8	3.4 ± 0.8	8.3 (1/12)	1/1
3× mIL-12	13	5.2 ± 1.3	1.9 ± 1.3	0
3× EGT mIL-12	14	17.7 ± 5.4 ^‡	14.3 ± 5.4	50.0 (7/14)	7/7
IR 10 Gy	10	8.1 ± 1.5	4.8 ± 1.5	0
3× EP + IR	11	13.1 ± 1.9	9.7 ± 1.9	27.3 (3/11)	3/3
3× dsRed + IR	12	9.9 ± 1.8	6.5 ± 1.8	16.7 (2/12)	2/2
3× EGT dsRed + IR	12	25.7 ± 4.8 ^‡§	22.3 ± 4.8	25.0 (3/12)	3/3
3× mIL-12 + IR	14	10.2 ± 1.7	6.9 ± 1.7	7.1 (1/14)	1/1
3× EGT mIL-12 + IR	15	43.1 ± 28.8 ^‡§	39.8 ± 28.8 ^‡	86.7 (13/15)	13/13

Therapeutic groups: 10 Gy single dose irradiation (IR), triple electric pulse application alone (3× EP) or combined with irradiation (3× EP + IR), triple intratumoral injection of plasmid DNA coding for mIL-12 or dsRed alone (3× mIL-12, 3x dsRed) or combined with irradiation (3× mIL-12 + IR, 3× dsRed + IR), triple mIL-12 or dsRed gene electrotransfer alone (3× EGT mIL-12, 3× EGT dsRed) or combined with irradiation (3× EGT mIL-12 + IR, 3× EGT dsRed + IR).
N - Number of all mice in the group.
* - Tumor doubling time - only mice with tumors were included in calculation.
^** - Tumor growth delay - only mice with tumors were included in calculation.
^† - Cures were determined 100 days after the treatment.
^# - Resistance to secondary challenge – number of cured mice that were resistant to secondary challenge is shown.
^‡ - Statistical significant difference compared to control group (p < 0.05).
^§ - Statistical significant difference compared to IR 10 Gy (p < 0.05)

ISSN: 1471-2407